Insider sales are small relative to market cap but the timing, within days of a $225M discount offering, indicates insiders were comfortable selling after dilution. Watch for additional selling by C-suite and potential follow-on offerings. The CEO's option exercise also adds selling pressure.
QURE drugs
QURE drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Jul 7 $41.41entry
- T+1 · 4mo ago +5.02%α +5.33% · $43.49
- T+5 · 4mo ago +0.27%α −0.29% · $41.52
- T+20 · 4mo ago +6.40%α +5.07% · $44.06
- T+60 · due 7w ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three insiders at uniQure (QURE), including the CEO and Chief Medical Officer, sold a combined $1.67M in stock within a week of a $225M dilutive offering. CEO Kapusta also exercised options in a cashless transaction. The cluster is small relative to the $2.6B market cap (~0.06%) but carries negative signal due to its proximity to the capital raise, which was priced at a 7.2% discount to market.
Key Financial Metrics
Key Facts
- Three insiders sold a total of $1.67M in QURE stock over 7 days (ending 2026-07-02).
- CEO Matthew Kapusta sold $953K (net of option exercise) across three open-market trades on the same day (2026-07-02).
- Director Jack Kaye sold $792K on 2026-06-30.
- Chief Medical Officer Walid Abi-Saab sold $465K on 2026-06-30.
- The stock offering (424B5) priced 4.95M new shares at $45.50 on 2026-06-23, a 7.2% discount to the prior close.
- Total insider sales represent ~0.06% of QURE's $2.6B market cap, below the 0.1% materiality threshold.
- No 10b5-1 plans were disclosed for these sales.
Financial Impact
Insider sales of $1.67M, or ~0.06% of market cap, executed after a $225M dilutive offering at a discount.
Risk Factors
- Additional insider selling from recently vested shares
- Near-term equity overhang from the 7.8% dilution in the June 2026 offering
- Sentiment overhang from insiders selling after a capital raise
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-QURE-1783490792917 |
Track record
38 reports on QURE
6 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +27.15% at T+20 after the Jul 29, 2026 report. 8 of 10 went positive at some point.
Filters
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 6/10 Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
- Nov 2, 202614d ago 8-K Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Nov 2, 202614d ago Press Release Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
- Sep 2, 202610w ago 8-K Bullish 7/10 Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
- Jul 29, 202615w ago 8-K Bullish 8/10 Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
- Jul 7, 202619w ago Insider Cluster Bearish 5/10 Viewing Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 4/10 Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers